Feeds:
Posts
Comments

Posts Tagged ‘multiomics platforms’

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:00 – 1:50

Lunch & Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

1:50-4:05

SESSION 4

From Targets to Trials:
Translating Discovery into Impact

1:50-2:10

Beyond Checkpoint Inhibitors: Targeted Immunotherapeutic Approaches for the Management of Solid Tumors

Andrea Ferreira-Gonzalez

2:10-2:30

Implementing Molecular Profiling in Early Phase Clinical Trials: Precision from Bench to Bedside

Andrea Ferreira-Gonzalez

2:30-2:40

Q&A

Andrea Ferreira-Gonzalez
Andrea Ferreira-Gonzalez

2:40-3:20

Non- CME Session: Venture Philanthropy

Andrea Ferreira-Gonzalez

Eric Heil, MBAManaging PartnerMedical Excellence Capital

John Lehr, President & CEO, Parkinson's Foundation

John LehrPresident & CEOParkinson’s Foundation

Dr. Blaine Robinson

Dr. Blaine Robinson, PhDVice President of the Therapy Acceleration Program (TAP)Blood Cancer United

3:20-4:10

eNSCLC Testing

Andrea Ferreira-Gonzalez

4:10 – 4:25

Break and Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

4:25-6:45

4:25-5:15

Transforming Pediatric Oncology: The Power of Precision Medicine

Andrea Ferreira-Gonzalez

Giselle L. Sholler, MD, Division Chief, Pediatric Hematology/Oncology/BMT, Penn State Hershey Children’s Hospital; Professor, Pediatrics and Pharmacology; Founder & Chair, Beat Childhood Cancer Consortium

Andrea Ferreira-Gonzalez

Wei Zhang, PhD, Hanes and Willis Family Professor in Cancer; Director, Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center

Andrea Ferreira-Gonzalez

Elias Sayour, MD, PhD, Professor, Neurosurgery and Pediatrics;  Assistant Dean,  Clinical Research, UF College of Medicine, Program Co-leader,  UF Health Cancer Center Immuno-Oncology and Microbiome (IOM) Program

Andrea Ferreira-Gonzalez

Milan Radovich, PhDSenior Vice President, Chief Scientific OfficerCaris Life Sciences

Andrea Ferreira-Gonzalez

Pei Wang, PhDProfessor, Genetic and Genomic SciencesIcahn School of Medicine at Mount Sinai

Abigail Moore

5:15-5:25

Informing therapy decisions for improved patient care

Ashley Varghese, PharmD, RPh

5:25-5:50

Liquid Biopsies and Resistance Monitoring in Targeted Therapies 

Andrea Ferreira-Gonzalez

Pashtoon Kasi, MD, MS, Medical Director, GI Medical Oncology, City of Hope

5:50-6:10

Liquid Biopsies in Clinical Practice: Transforming Precision Oncology Through Molecular Monitoring

Andrea Ferreira-Gonzalez

Hatim Husain, MD, Associate ProfessorUniversity of California, San Diego 

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, MidMorning Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

0:40 – 11:10

Break and Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

11:10 – 1:10

SESSION 2

The Evolution of Precision Oncology:

Integrating MRD, AI, and Beyond

11:10-12:00

Precision Cancer Consortium

Andrea Ferreira-Gonzalez
Andrea Ferreira-Gonzalez

Shruti Mathur, MSPharma Diagnostic Strategy Leader, Global Product Strategy (GPS), Genentech

Andrea Ferreira-Gonzalez

Daryl Pritchard, PhD, Interim President, Personalized Medicine Coalition

Andrea Ferreira-Gonzalez

Keith T. Flaherty, MD, FAACR, Director of Clinical Research, Massachusetts General Cancer CenterProfessor of Medicine, Harvard Medical School;
President-Elect: 2025-2026, American Association for Cancer Research (AACR) 

SESSION 3

The Shifting Landscape:

Tumor Plasticity and Resistance

12:00-12:20

Mathematical and Evolutionary Modeling in Precision Radiation Oncology

Andrea Ferreira-Gonzalez

Jacob Scott, MD, DPhil, Professor and Staff Physician-Scientist, CWRU School of Medicine and Cleveland Clinic

12:20-12:40

Plasticity and Persistence: The Role of EMT in Cancer Progression and Therapy Resistance

Andrea Ferreira-Gonzalez

Sendurai A. Mani, PhD, Professor of Pathology and Laboratory Medicine, Brown University; Associate Director of Translational Oncology, Brown University Legorreta Cancer Center

12:40-1:00

Targeting Molecularly Defined Subsets: Challenges in Translational Oncology

Andrea Ferreira-Gonzalez

Benedito A. Carneiro, MD, MS, Director, Clinical Research
Director, Cancer Drug Development; Associate Director, Division of Hematology/Oncology
Legorreta Cancer Center, Brown University Health

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Early Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

 

8:55 – 10:35

SESSION 1

Precision For All:

Global Access, Real Cases, and Implementation Science

 

8:55-9:15

Results and Future Direction from WIN’s Data Science Paper

Razelle Kurzrock, MD

9:15-9:55

When Precision Gets Personal: WIN Consortium International Molecular Tumor Board Live

Andrea Ferreira-Gonzalez
Razelle Kurzrock, MD

Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium; Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, MCW Cancer Center and Linda T. & John A. Mellowes Center for Genomic Sciences and Precision Medicine

Notes from Live Tumor Board from Live Tweets

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

Tumor board Live . Oncologists don’t always accept tumor board recommendations based on molecular profiling… Dr Baptiste at first felt constrained to use single agent but WINTER combo trial with molec profiling better

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

Pemetrexemed not always working but MTAP inhibitions may work

Tumor board Live… Discussion of ovarian cancer case women first presented with CRC BRCA mut but failed PARP inhibitor board is looking at immunotherapy NGS IHC performed

#WINconsortium

Fusions being detected by RNAseq at rate of 100 per month

Tumor board Live…. Theranostics are becoming part of molec tumor board … Radio labeled dual diagnostic therapeutic antibodies

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

SESSION 2

Expanding the Precision Frontier

9:55-10:25

Precision Oncology in the Immunotherapy Era: Biomarkers and Clinical Trial Innovation

Razelle Kurzrock, MD

Lillian Siu, MD, President, AACR 2025-2026; Director, Phase I Clinical Trials Program; Co-Director, Robert and Maggie Bras and Family Drug Development Program Clinical Lead, Tumor Immunotherapy Program; BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre Professor of Medicine, University of Toronto

  • Princess Margaret CC went to Merck got pembrolizumab from them but built a team platform of clinicians and scientists to work on INSPIRE trial
  • $11 million of grants, 13 major papers, great team science
  • did ctDNA from liquid biopsy and also looked at methylation patterns in cfDNA
  • looked at IFN stimulation and outcome to pembrolizumab
  • retro transposable elements found in INSPIRE program, maybe a predictor of immune sensitivity
  • they were able to correlate some of their findings with spatial omics
  • using spatial data they could look at hot versus cold head and neck cancer
  •  factors for response to immunotherapy: TMB, t cell infiltrate,  PDL1 etc
  • using AI with IHC slides as well as NGS data sets
  • as clinical trials become multiomics and AI with multiomics platforms data sharing will be critical for success

10:25 – 10:35

The Microbiome and Its Role in Cancer Development and Treatment Response

Razelle Kurzrock, MD

Sabine Hazan, MD, CEO, Ventura Clinical Trials; CEO, Progenabiome

  • microbiome research at the infancy so we don’t know much when comes to oncology
  • we need to compare microbiome between persons using NGS and other omics
  • we all have different microbiome even though microbiome ‘healthy’
  • lots of factors affect microbiome including surgery
  • families are similar in their microbiome but when looking at Alzheimers there are differences
  • first lab to find whole COVID in the stools
  • virus was different in different people, difference spike proteins. Virus mutates from lung to stool (gut)
  • in intrafamily patients had different microbiome upon COVID infection
  • bifodobacteria was found as a major part of microbiome altered in COVID but also lots of other diseases
  • lots of examples of host microbial symbiosis
  • they had an instance with throat tumor treated with microbiome and tumor receded without chemo
  • in a glioblastoma microbiome adjustment helped but changed positive response to immunotherapy

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Omics Session Track 2 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

4:20-4:40

Andrea Ferreira-Gonzalez

 

  • APOE was marker for defining a long term survivor and short term survivor for ovarian cancer patients; the markers were in the stroma
  • there is spatial communication between tumor and underlying stroma
  • it is imperative to understand how your multiomics equipment images a tumor area before it laser captures and send to the MS system; can lose a lot of tissue and information based on differences in resolution
  • many of these multiomics systems are validated for the clinic in EU not US
  • multiomics spatial analysis allows you to image protein, metabolite, mRNA expression in the 3 dimensional environment of the tumor (tumor cells and stroma)
  • they are making a human tumor atlas
  • they say a patient who had tumor went home during COVID and took vaccine but got ill with vaccine; but came back to check tumor and tumor had greatly regressed because prevaccine the tumor was immunologically cold and post COVID vaccine any left over tumor showed great infiltration of immune cells

4:40-4:55

Andrea Ferreira-Gonzalez

Aruna Ayer, PhDVP, Multiomics, Innovation and Scientific AffairsBD Biosciences

  • BD Bioscience multiomics platform is modular and can add more omics levels in the platorm
  • for example someone wanted to look at T cells
  • people have added CRISPR screens on the omics platform
  • most people are using single cell spatial omics
  • they have a FACS on their platform too so you can look at single cell spatial omics and sort different cellular populations
  • very comparative to 10X Genomics platform
  • their proteomics is another layer you can add on their platform however with proteomics you can high background notice with spatial proteomics or a limited panel of biomarkers
  • Their OMICS Protein One panels are optimized for biology and tumor type.
  • get high quality multiomics data and proteomics data but in a 3D spatial format
  • developed Cellismo Data Visualization software tool

4:55-5:10

Andrea Ferreira-Gonzalez

Harsha Gowda, PhDSenior Principal Scientist, Director, Research & Lab Operations, Signios Bio

Signios Biosciences (Signios Bio) is the US-based arm of MedGenome, a global leader in genetic testing services, genomics research, and drug discovery solutions.

Signios Bio is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data. We leverage the power of multiomics—integrating data from genomics, transcriptomics, proteomics, epigenomics, metabolomics, and microbiomics—to gain a comprehensive understanding of disease biology. Our AI-powered bioinformatics platform allows us to efficiently analyze these complex datasets, uncovering hidden patterns and accelerating the development of new therapies and diagnostics.

Through the integration of cutting-edge multiomics technologies, advanced bioinformatics, and the expertise of world-class scientists, we enable researchers and clinicians with comprehensive, end-to-end solutions to improve drug discovery and development and advance precision medicine.

As part of MedGenome, we have access to real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America. This access enables us to work with our partners to uncover insights that can lead to new biomarkers and drug targets, ensuring that precision medicine is inclusive and effective for all.

https://www.signiosbiolcom 

  • their platform can do high throughput analysis of patient tumors (like gallbladder cancer) analyzing mutational spectrum with high dimensionality
  • they can integrate genomic and transcriptomics data to reveal multiple pathways affected in patient data
  • have used their platform to investigate spatial omics in lung cancer

Read Full Post »